Accuracy rates of the RASGRP1/APTX gene pair as a predictor of response to tipifarnib in AML
| . | Clinical response . | Total . | |
|---|---|---|---|
| PD . | R . | ||
| Newly diagnosed AML* | |||
| Predicted R | 0 | 12 | 12 |
| Predicted PD | 13 | 1 | 14 |
| Total newly diagnosed | 13 | 13 | 26 |
| Relapsed or refractory AML† | |||
| Predicted R | 21 | 8 | 29 |
| Predicted PD | 23 | 2 | 25 |
| Total relapsed or refractory | 44 | 10 | 54 |
| . | Clinical response . | Total . | |
|---|---|---|---|
| PD . | R . | ||
| Newly diagnosed AML* | |||
| Predicted R | 0 | 12 | 12 |
| Predicted PD | 13 | 1 | 14 |
| Total newly diagnosed | 13 | 13 | 26 |
| Relapsed or refractory AML† | |||
| Predicted R | 21 | 8 | 29 |
| Predicted PD | 23 | 2 | 25 |
| Total relapsed or refractory | 44 | 10 | 54 |
R and PD represent responders and patients with progressive disease, respectively.
For newly diagnosed AML, sensitivity was 92.3%; specificity, 100%; NPV, 92.9%; PPV, 100%; and prevalence, 50%.
For relapsed or refractory AML, sensitivity was 80%; specificity, 52.3%; NPV, 92%; PPV, 27.6%; prevalence, 18.5%; and odds ratio, 4.4.